Search
Somatrem
go.drugbank.com/drugs/DB09098ApprovedWithdrawncontinues to be mired in persistent bioethical debate [A32292]. … Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents
Mixtures: Protropin Pws 5mg/vial, Protropin - Kit Im Sc 5mg/vialToripalimab
go.drugbank.com/drugs/DB15043ApprovedInvestigationalIt was first approved in China in December 2018 for the treatment of unresectable or metastatic melanoma in previously treated patients. … The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance.
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalinclude lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. … It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to
Products: LORBRENA® 25 MG, LORBRENA® 100 MGLixisenatide
go.drugbank.com/drugs/DB09265ApprovedInvestigationalIt is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763] … Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM).
Mixtures: Suliqua Pen, Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled penCategories: Drugs Used in DiabetesChlorobutanol
go.drugbank.com/drugs/DB11386ApprovedVet approvedWithdrawnSimilar in nature to chloral hydrate, it is formed by the simple nucleophilic addition of chloroform and acetone. … It also elicits sedative-hypnotic and weak local anesthetic actions in addition to antibacterial and antifungal properties.
Mixtures: NOSTIL 75 MG/60MG/35MG BURUN SPREYİ, ÇÖZELTİ, 15 MLCategories: Compounds used in a research, industrial, or household settingSulfamethoxazole
go.drugbank.com/drugs/DB01015ApprovedInvestigational[L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps … in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance.
Mixtures: COTRIM E RATIO 480MG/5ML, EUSAPRIM E SUSPENS F ERWSynonyms: 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamideOsimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalIn contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. … Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.
Synonyms: N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamideProducts: TAGRISSO® 40 MG, TAGRISSO® 80 MG.Ethionamide
go.drugbank.com/drugs/DB00609ApprovedInvestigationalWithdrawnA second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)
Synonyms: ETH, ETPProducts: ETIONAMIDA TABLETAS 250 MG, ETYOMID 250 MG DRAJE, 50 ADETChondroitin sulfate
go.drugbank.com/drugs/DB09301ApprovedInvestigationalNutraceutical[A32063] Chondroitin sulfate is sold as an OTC dietary supplement in North America and it is a prescription drug under the EMA in Europe.[A32066] … Depending on the predominating disaccharide unit, it will present different biological activities.
Mixtures: flexijoint 3-in-1 Joint Care Powder, OSTEOACTIV 3-in-1 Joint Formula PowderProducts: Cartexan 400 mg Hartkapseln, Condrosulf 400 mg - KapselnIpratropium
go.drugbank.com/drugs/DB00332ApprovedInvestigational] was approved in 1996. … [A176939] It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption.
Mixtures: SALBUTAMOLO E IPRATROPIO BROMURO EG, Otrivin Duo 0,5 mg/ml + 0,6 mg/ml Nasenspray, LösungProducts: ATROVENT 500 MG /2ML, Nasipral 0,3 mg/ml Nasenspray, Lösung